At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 910 enrolled
Drug / intervention
AZD7442 +1 moredrug
Likely dose
AZD7442 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults
In Brief
A Phase 3 clinical trial evaluating AZD7442 and Placebo for COVID-19. Completed, enrolled 910 participants across 103 sites in 15 countries.
Detailed Summary
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesArgentina, Brazil, Czechia, Germany, Hungary, Italy, Japan, Mexico, Peru, Poland, Russia, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJan 2021
Primary CompletionAug 2021
Study CompletionOct 2022
TodayJul 2026
First PostedJan 25, 2021
Enrollment StartJan 28, 2021
Primary CompletionAug 21, 2021
Study CompletionOct 19, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.4 years ago
Interventions
AZD7442drug
Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
Placebodrug
Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.